# Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

> **NCT06997094** · PHASE1 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 24 (estimated)

## Conditions studied

- Human Papillomavirus-Negative Neck Squamous Cell Carcinoma
- Resectable Head and Neck Squamous Cell Carcinoma
- Resectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma
- HPV-Negative Squamous Cell Carcinoma
- Resectable Head and Neck Squamous-cell Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Chemotherapy
- **DRUG:** Decitabine
- **RADIATION:** External Beam Radiation Therapy
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Surgical Procedure

## Key facts

- **NCT ID:** NCT06997094
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-23
- **Primary completion:** 2027-11-08
- **Final completion:** 2027-11-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06997094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06997094, "Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06997094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*